These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 31370980)

  • 21. Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.
    Larochelle MR; Wakeman SE; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    Med Care; 2020 Oct; 58(10):919-926. PubMed ID: 32842044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review.
    Ghabrash MF; Bahremand A; Veilleux M; Blais-Normandin G; Chicoine G; Sutra-Cole C; Kaur N; Ziegler D; Dubreucq S; Juteau LC; Lestage L; Jutras-Aswad D
    J Dual Diagn; 2020; 16(2):191-207. PubMed ID: 32089124
    [No Abstract]   [Full Text] [Related]  

  • 24. Financial factors and the implementation of medications for treating opioid use disorders.
    Knudsen HK; Roman PM
    J Addict Med; 2012 Dec; 6(4):280-6. PubMed ID: 22810057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vermont responds to its opioid crisis.
    Simpatico TA
    Prev Med; 2015 Nov; 80():10-1. PubMed ID: 25869219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
    Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
    Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
    Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S
    J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
    Huo S; Heil J; Salzman MS; Carroll G; Haroz R
    J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
    Winhusen T; Wilder C; Wexelblatt SL; Theobald J; Hall ES; Lewis D; Van Hook J; Marcotte M
    Contemp Clin Trials; 2014 Sep; 39(1):158-65. PubMed ID: 25183042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients.
    Kelly SM; Brown BS; Katz EC; O'Grady KE; Mitchell SG; King S; Schwartz RP
    Am J Drug Alcohol Abuse; 2012 May; 38(3):233-8. PubMed ID: 22242643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients.
    Tkacz J; Volpicelli J; Un H; Ruetsch C
    J Subst Abuse Treat; 2014 Apr; 46(4):456-62. PubMed ID: 24332511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
    Samples H; Williams AR; Olfson M; Crystal S
    J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
    Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
    Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.
    Jones NR; Shanahan M; Dobbins T; Degenhardt L; Montebello M; Gisev N; Larney S
    Drug Alcohol Rev; 2019 Sep; 38(6):690-698. PubMed ID: 31577058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.
    Shastry S; Manini AF; Richardson LD; Lin MP
    J Gen Intern Med; 2020 Mar; 35(3):965-966. PubMed ID: 31414352
    [No Abstract]   [Full Text] [Related]  

  • 38. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.
    Hickman M; Steer C; Tilling K; Lim AG; Marsden J; Millar T; Strang J; Telfer M; Vickerman P; Macleod J
    Addiction; 2018 Aug; 113(8):1461-1476. PubMed ID: 29672985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Reimbursement of opiate substitution drugs to militaries in 2007].
    d'Argouges F; Desjeux G; Marsan P; Thevenin-Garron V
    Encephale; 2012 Sep; 38(4):304-9. PubMed ID: 22980471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.